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doi:10.1016/j.jtcvs.2007.01.002bjective: Rotary axial flow pumps have several potential advantages and disad-
antages over pulsatile pumps. The Jarvik 2000 is distinctive in being intracardiac.
e report our experience in 22 patients.
ethods: The Jarvik 2000 was implanted in 15 men and 7 women. Mean age was
8.8 (range 23–59) years, preoperative diagnosis was dilated cardiomyopathy in 16,
ostpartum cardiomyopathy in 3, ischemic heart disease in 2, and chronic allograft
ailure in 1. Twenty-one patients were in New York Heart Association class IV, and
patient was in class III. Nineteen patients were on inotropic support, 6 were
upported with an intra-aortic balloon pump, and 2 patients had been salvaged with
Centrimag (Levitronix) ventricular assist device. The median pulmonary vascular
esistance was 3 Wood units; median pulmonary capillary wedge pressure was 26.6
m Hg; and mean Cardiac Index was 1.5 L/min/m2.
esults: There were 2 early deaths and 6 late deaths. The average postoperative
entilation time and Intensive Treatment Unit stay was 2.2 and 10 days, respec-
ively. One patient required a right ventricular assist device for short-term support
nd another for medium-term support. Seven patients were bridged to transplant, 3
ad myocardial recovery, and 4 are ongoing. Mean and total duration of support was
80.5 and 6172 days, respectively. Driveline failures were noted in 3, but there were
o pump infections or failure.
onclusion: The Jarvik 2000 provides satisfactory intermediate-term results as a
ridge to transplant or recovery. It appears to be associated with a low rate of serious
riveline or pump infections and technical failure. However, bleeding complications
ue to the required anticoagulation treatment frequently occurred.
he choice of left ventricular assist device (LVAD) remains controversial. In
an attempt to address the limitations of pulsatile LVADs, axial flow pumps
have been developed in recent years with a steady increase in their clinical
se. The Randomized Evaluation of Mechanical Assistance for the Treatment of
ongestive Heart Failure (REMATCH) trial showed that pulsatile LVADs resulted
n a 2-year survival of 23% in patients with end-stage heart disease compared with
% for patients not receiving an LVAD but on optimal medical management. But
hese first-generation pulsatile pumps were associated with a significant number of
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TXdverse events.1 The increasing use of ventricular ass
evices in patients with end-stage heart failure provides an
mpetus to improve the performance of these devices for
oth short- and long-term use.
Axial flow pumps are generally smaller devices than the
ulsatile pumps and may be associated with a lower inci-
ence of complications.2-9 A recent early experience wi
he Incor (Berlin Heart, Berlin, Germany) LVAD in 24
atients has been reported with an acceptable level of com-
lications.9 The Jarvik 2000 (Jarvik Heart, Inc., New Y
Y) is a lower-flow device than the larger pulsatile pumps,
roviding an average flow of 3 to 4 L (max 6 to 7 L). The
urgical trauma of implantation is lower than that with the
arger devices. The pump is placed inside the left ventricle,
voiding the need for an inflow cannula, and the outflow
raft can be connected either to the ascending or descending
orta. Furthermore, the smaller-diameter driveline is likely
o be associated with a lower infection rate.
The aim of this study was to evaluate our clinical expe-
ience with the Jarvik 2000 axial flow pump implanted in a
otal of 22 patients between May 2003 and April 2006.
aterials and Methods
e retrospectively reviewed 22 patients implanted with the Jarvik
000 LVAD between May 7, 2003 and May 7, 2006. Approval to
mplant the device was provided by the hospital clinical practice
ommittee. Approval was also obtained by the Medicines and
ealthcare Products Regulatory Agency. Informed consent was
btained from each patient.
evice Description
he pump consists of a small electromagnetically, implantable
itanium (25 cm3, 90 g) intraventricular axial flow (single rotating
aned impeller) blood pump providing on average 3 to 4 L/min
ow with a maximum flow of 6 to 7 L/min at 4 to 7 W of power
gainst physiologic pressure.
The extraperitoneal power cable lead exits transcutaneously
hrough the midpoint between the right upper and right lower
bdominal quadrant and connects to the external controller.
emographics
ifteen patients were men and 7 were women. Mean age was 38.8
range 23–59) years. The diagnosis was dilated cardiomyopathy in
Abbreviations and Acronyms
CVA  cerebrovascular accident
IHD  ischemic heart disease
INR  international normalized ratio
LVAD  left ventricular assist device
REMATCH Randomized Evaluation of Mechanical
Assistance for the Treatment of
Congestive Heart Failure6 (72.7%), postpartum cardiomyopathy in 3 (13.6%), Ischemic s
00 The Journal of Thoracic and Cardiovascular Surgery ● Julyeart disease (IHD) in 2 (9.1%), and chronic allograft failure in 1
4.5%). Twenty-one (95.4%) patients were in New York Heart
ssociation class IV and 1 (4.6%) was in class III. One patient was
echanically ventilated (4.5%), 20 (90.9%) patients were on ino-
ropic support, 6 (27.2%) patients required a preoperative intra-
ortic balloon pump, and 2 (9.1%) had support with a Centrimag
Levitronix, Zurich, Switzerland) centrifugal pump as a salvage
nd bridge-to-decision procedure.
Mean height was 173.7  10.4 cm (157–185), mean weight
as 70.0  7.0 kg (60–74.8), and the mean body mass index was
3.2  1.9 kg/m2 (21.9–27.6).
Mean preoperative alanine transferase was 140.5 216.2 IU/L
13–1344) and the mean bilirubin was 2.3  1.4 mg/L (0.29–
.49). Creatinine was 1.41  0.59 mg/L (0.45–2.94) and urea was
1  20 mg/L (8.68–70.3). Mean serum albumin was 3.0  0.6
/dL (1.9–4.2).
Preoperative hemodynamic data revealed a mean pulmonary
ascular resistance of 3.5  2.7 Wood units (1.4–11.7), transpul-
onary gradient of 7.6  7.1 mm Hg (4–24), pulmonary capillary
edge pressure 26.6  6.7 mm Hg (14–44), and cardiac index
as 1.5  0.3 L/min/m2 (1.1–2.3).
Preoperative transthoracic echocardiography showed a mean
eft ventricular end-diastolic dimension and end-systolic dimen-
ion of 68.5 mm and 62.4 mm, respectively.
urgical Approach
median sternotomy with an ascending aortic anastomosis was
erformed in 19 patients and a left thoracotomy with a thoracic
escending aortic anastomosis in the other 3 patients. The LVAD
as implanted in 3 patients without the use of the cardiopulmonary
ypass. In 6 patients, tricuspid valve annuloplasty was performed
ith the use of a standard Carpentier’s ring size 32 for women and
4 for men. The cable power drivelines in all patients were
ntroduced through the extraperitoneal abdominal wall, surfacing
ercutaneously through the midpoint between the right upper and
ight lower abdominal quadrant and connects to the external
ontroller.
ostoperative Monitoring
ll patients received peri- and postoperative hemodynamic mon-
toring and evaluation. A central venous line was used to assess the
ight heart filling pressures, and a Swan–Ganz catheter (Arrow
nternational Inc., Reading, Pa) (in some patients) was used to
ssess cardiac output, pulmonary pressure, and systemic vascular
esistance. However, a continuous transesophageal echo, by leav-
ng the transesophageal echo probe in place during the first 48
ours after the operation, was the most valuable tool to assess
lling of the right and left ventricles, right ventricular function,
nd septal deviation. The pump speed was generally kept low
speed setting 2; 9000 rpm) for all patients throughout the surgery,
articularly when the chest was still open, to avoid any air suction
o the left ventricle through the apex suture line, though bioglue
as applied to minimize any further suction. However, in the later
tages, the speed of the pump was adjusted, mainly by assessing
he mean blood pressure, left ventricular filling and/or collapse, the
eptal deviation, and right ventricular filling and contractility.
ost patients were given, at a later stage, adequate circulatoryupport at a speed setting of 3 (10,000 rpm) when intravascular
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TXolume filling and right ventricular function were adequate. When
atients were ambulated, some were increased to a pump speed of
(11,000 rpm). Intermittent pulsatility and aortic root ejections
ere maintained by applying the intermittent low-speed
ontroller.10
nticoagulant Treatment
eparin treatment began the following day after surgery (target
rothrombin time 2.0–2.5 times normal) and was subsequently
onverted to warfarin and 75 mg aspirin daily. The target range for
nternational normalized ratio (INR) was 2.5 to 3.5. If the INR
ropped to 2.0 to 2.5, half-dose low-molecular-weight heparin was
dministered, and if the INR dropped under 2, a full dose of
ow-molecular-weight heparin was given. Antiplatelet inhibition
onitoring was performed in selected cases when bleeding com-
lications occurred.
tatistical Analysis
ata are presented as mean or when indicated as median with
tandard deviation and range.
esults
he mean duration of support was 280.5  232.3 days
range 6–683), and the total duration of support was 6172
atient-days. There were 2 early deaths as a result of sepsis
nd multiorgan failure following 8 and 23 days of support,
espectively. There were 6 late deaths. One patient had a
hest infection, which led to disseminated intravascular
oagulation (DIC), and she died from a frontal lobe bleed
fter 44 days of support. A second patient developed bowel
istension complicated by gastrointestinal bleeding, and he
ied after 84 days of support. A third patient had a bleed
ollowing the removal of epicardial pacing wires and devel-
ped acute tamponade, which required emergency explora-
ion, complicated by multiorgan failure, and she died after
0 days of support. A fourth patient had a salvage pneumo-
ectomy to secure intrapulmonary bleeding, and he died
fter 136 days of support. The fifth patient died from a
emorrhagic cerebrovascular accident (CVA) after 560 days
f support. The sixth patient died due to device power cable
ailure, which occurred in the community after 291 days of
upport.
One patient (4.5%) required a right ventricular assist
evice (RVAD) for a short period of support (which was
xplanted 7 days later), and another continued having
VAD Levitronix support while the LVAD Levitronix was
pgraded to a Jarvik LVAD. The mean duration of nitric
xide treatment was 1.4 days (range 1–3) days. The mean
uration of ventilation was 52 51.8 hours (range 12–168),
nd mean intensive care unit stay was 10  13.6 days with
range of 2 to 48 days.
The median perioperative (during and 24 hours after the
urgery) blood products transfused per patient were: 1.0 
.2 U of platelets, 3.6  4.1 U of fresh frozen plasma, and
.8  4.2 U of packed red blood cells. d
The Journal of Thoracicridge to Transplant
even patients were bridged to orthotopic heart transplant
fter 92, 102, 116, 330, 409, 641, and 828 days of support.
ix were successfully bridged, and the seventh died due to
rimary graft dysfunction.
ridge to Recovery
wo patients with postpartum cardiomyopathy and one with
ilated cardiomyopathy recovered after 253, 407, and 683
ays of support, respectively. In all 3 cases, the device was
eft in situ by ligating the outflow line and most of the
riveline was removed. All 3 patients are well and alive
fter a postexplant follow-up of 295, 446, and 567 days,
espectively.
ome Discharge
hirteen (59%) patients were discharged home while on
upport. Four patients are currently on ongoing support (3 of
hem at home) at 305, 319, 341, and 381 days of support.
omplications
Thromboembolism. Among the 3 patients who had de-
cending aortic anastomosis, 1 developed an extensive clot
n the ascending aorta and another had an embolic CVA
fter 560 days of support. Left ventricular thrombus was not
oted in any of the patients.
Bleeding. Nine patients (41%) required reexploratory
urgery for bleeding. Two patients (in addition to the patient
ith DIC described above) had frontal lobe bleeds, 1 patient
ad an occipital lobe bleed, 1 patient experienced gastroin-
estinal bleeding, and another patient was treated for a
ediastinal bleed and tamponade that followed the removal
f epicardial pacing wires.
Infections. Minor superficial driveline infections were
oted and treated with antibiotics without the need for
ospital readmission. One patient who developed mediasti-
itis and driveline infection was treated with intravenous
ntibiotics and drainage through a minimal surgical explo-
ation. However, there were no pump housing or outflow
ine infections while on support.
Technical and pump failure. One patient experienced
cute failure of the abdominal extension power cable after
93 days of support while in the community awaiting trans-
lant. Another patient experienced partial failure of the
mplanted power lead close to the external connection. This
esulted in several transient episodes of loss of function of
he device. He was readmitted to the hospital, but no ad-
erse clinical consequences occurred. The patient was sub-
equently successfully transplanted after 330 days of sup-
ort. A third patient experienced driveline fracture and
ailure and had emergency surgical disconnection of the
evice (leaving it in situ) to prevent reverse flow after 683
ays of support, as he had sufficient myocardial recovery.
and Cardiovascular Surgery ● Volume 134, Number 1 201
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TXe was successfully discharged home following this. No
ncidences of pump failure occurred.
iscussion
ur intermediate experience with the Jarvik 2000 has been
ncouraging, with relatively low rates of surgical trauma,
ump infection, and pump failure and good device durabil-
ty with a low rate of driveline infection. Our selection of
his device was influenced by its distinct advantage of being
n intraventricular, small-size, axial flow pump with no
nflow cannula or chamber. Previous and concurrent clinical
ses of this device in other centers have suggested satisfac-
ory outcomes.11-15
Selecting a particular device from the variety of devices
vailable is often challenging.16 Among the factors tha
nfluence the selection and use of a particular device are: the
ize of the patient, concurrent right ventricular dysfunction,
otential for hospital discharge, predicted duration of sup-
ort and the likelihood of recovery or destination therapy,
he required anticoagulant treatment, the experience of the
mplanting center in a specific type of device, and the cost
f the procedure and device.
The REMATCH trial rendered the pulsatile pumps (spe-
ifically the HeartMate I [Thoratec, Pleasanton, Calif]) as
he gold standard and benchmark for mechanical assist
upport for end-stage heart failure.1 However, the success o
hese pumps was limited by a significant rate of device-
elated complications. In particular, infection, bleeding, and
echanical failure of the device were major factors in the
-year survival rate of only 23%. In an attempt to reduce
hese frequent and serious complications and to simplify the
evice insertion and minimize the associated surgical
rauma, improve function, and durability and expand the
otential pool of patients that can be candidates for support,
xial flow pumps have evolved and have been introduced
nto clinical practice. The Incor, HeartMate II, MicroMed
eBakey (MicroMed Cardiovascular Inc, Houston, Tex),
nd the Jarvik 2000 devices are the most frequent axial flow
evices in recent clinical use.
In our experience, the surgical insertion was not complex
nd was simpler than that for the HeartMate (XVE) device.
e performed left thoracotomy and connected the outflow
raft to the descending aorta in the first 3 patients receiving
Jarvik device. This method of implanting the Jarvik (con-
ecting the outflow graft to the thoracic descending aorta
ia left thoracotomy) is reported by Frazier and colleagu14
ith satisfactory results. However, there were 2 main rea-
ons that made us change to median sternotomy, which
nvolves connecting the outflow graft to the ascending aorta.
irst, in our early experience, 2 out of 3 patients experi-
nced thromboembolic complications (1 patient had ascend-
ng aortic clot and the other had an embolic CVA), and l
02 The Journal of Thoracic and Cardiovascular Surgery ● Julyecond, it gave us the flexibility to insert an RVAD if
ecessary through the median sternotomy.
The LVAD Jarvik was inserted in 3 patients without the
se of cardiopulmonary bypass. All patients survived and
VAD support was not needed in these cases. Off-pump
VAD insertion could be safely used when the patient was
ble to tolerate lifting of the heart to allow exposure and
asy access to the apex.
We experienced a high rate of acute postoperative bleeding
espite minor surgical trauma, which could be explained partly
y the high incidence of preoperative liver dysfunction among
ur group of patients. Late bleeding was all related to the
equired anticoagulation treatment. A 42% frequency of post-
perative bleeding occurred in the REMATCH trial, and re-
peration for bleeding was reported by Goldstein17 as the mos
ommon complication following implantation of the Mi-
roMed Debakey LVAD.1
Driveline and device pocket infections are frequent, se-
ious, and challenging complications for assist devices in
eneral and pulsatile pumps in particular. We, like others,
ound a low rate of driveline and device-related infec-
ion.18,19 The small size of the device and the lac
bdominal pocket, inflow cannula, or valves combined with
n insertion that is associated with relatively minor surgical
rauma with a flexible and stable driveline are among the
actors that contribute to a low rate of serious infection with
his device.
Among the pulsatile pumps, the REMATCH investiga-
ors reported that sepsis in particular was one of the major
actors in the 2-year survival rate of only 23%.1 On the othe
and, the experience with a large series of the MicroMed
ebakey axial flow pumps showed a particularly low rate of
evice-related infections and sepsis.17 In an earlier labora-
ory and clinical experience with the Jarvik 2000 device, it
as reported that rigid fixation and the vascularity of scalp
kin promoted healing and reduced the risk of driveline
nfection.18-20 However, as we mentioned previously, o
referred percutaneous driveline exit site was the abdominal
all mainly due to the simplicity of the procedure.
With the Jarvik 2000, we experienced no pump failure,
lthough there were 3 (13.6%) driveline failures. The re-
orted experience with the MicroMed Debakey and Incor
howed a low rate of device mechanical failure.9,17 The
auses of mechanical failure in the MicroMed Debakey
ump included a recessed connector pin (n  2), a broken
ire (n  1), and a controller failure (n  1).17 A controller
ntermittent malfunction was the only reported mechanical
ailure in the Incor pump.9 Mechanical failure continues t
e a major problem with the pulsatile devices despite im-
rovements in design .21 The probability of device failure 
uch devices was 35% in the REMATCH study at 24
onths, and the device was replaced in 10 patients.1 Theack of pump failure in our series is attributed mainly to the
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Haj-Yahia et al Cardiothoracic Transplantationasic design of the device, with the single movable compo-
ent being an impeller located in the center of the titanium
ousing.
Our primary goal for using the Jarvik 2000 was in
rinciple as a bridge to transplant. So far, we have bridged
patients (31.8%), 6 of them (85.7%) successfully. The
hortage of organs available for transplantation limited
ridging higher numbers of patients. However, the small
ize of the device and low rate of driveline and pump
nfection are features of this device that also support its use
s destination therapy.22-24
One of the main concerns regarding the Jarvik 2000
iniaturized axial flow pump is whether it can provide
ufficient flow and support for day-to-day physical activity
s it provides lower flows than other devices. We feel that
he initial acute postoperative recovery rate (mainly inten-
ive care unit stay) is initially slightly faster due to lower
urgical trauma, blood transfusion, and so on, but the next
ecovery phase is slower in these devices, which could be
elated to it being a low-flow device. Later on, this device
rovided satisfactory flows and support for patients to main-
ain a reasonable quality of life and maintain good physical
ctivity at hospital and home. At present, 4 patients are on
ngoing support, and 3 are at home. The long battery life,
ight power source, and simple, small, user-friendly device
ontroller with no reported pump failure have made it
elatively easy to discharge patients home as soon as they
ecover. However, a longer period will be needed to eval-
ate the reliability and outcome of the device.
onclusions
he Jarvik 2000 LVAD gives satisfactory midterm results
imilar to other axial flow pumps. It has some advantages
ver the pulsatile pumps in terms of lower surgical trauma,
ump infection, and pump failure and durability. However,
ore clinical experience, longer follow-up, and further
valuation are needed.
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